In-silico trials with human modelling and simulation for guiding optimal stratification of atrial fibrillation patients to catheter ablation and pharmacological therapy
<p>Atrial fibrillation (AF) is the most prevalent sustained arrhythmia, affecting over 43 million people worldwide and one in 45 people in the UK. The modest efficacy of currently available therapies adds to the nature of the problem. Antiarrhythmic medication and catheter ablation are the two...
Váldodahkki: | Dasí i Martinez, A |
---|---|
Eará dahkkit: | Bueno Orovio, A |
Materiálatiipa: | Oahppočájánas |
Giella: | English |
Almmustuhtton: |
2023
|
Fáttát: |
Geahča maid
-
In-silico drug trials for precision medicine in atrial fibrillation: From ionic mechanisms to electrocardiogram-based predictions in structurally-healthy human atria
Dahkki: Albert Dasí, et al.
Almmustuhtton: (2022-09-01) -
Virtual In-Silico Modeling Guided Catheter Ablation Predicts Effective Linear Ablation Lesion Set for Longstanding Persistent Atrial Fibrillation: Multicenter Prospective Randomized Study
Dahkki: Jaemin Shim, et al.
Almmustuhtton: (2017-10-01) -
Commentary: Virtual In-Silico Modeling Guided Catheter Ablation Predicts Effective Linear Ablation Lesion Set for Longstanding Persistent Atrial Fibrillation: Multicenter Prospective Randomized Study
Dahkki: Axel Loewe, et al.
Almmustuhtton: (2017-12-01) -
Catheter Ablation for Atrial Fibrillation
Dahkki: Andre J. Gauri, et al.
Almmustuhtton: (2003-10-01) -
Editorial: Atrial fibrillation: insights on mechanisms, mapping and catheter ablation
Dahkki: Sergio Conti, et al.
Almmustuhtton: (2023-09-01)